A research team led by Professor Takuya Yamamoto (Department of Life Science Frontiers) and Professor Yasuhiro Yamada at the University of Tokyo has developed a novel in vivo system that reveals how ...

MiNK Therapeutics surged 730% on breakthrough testicular cancer data with agenT-797. Click here to read my analysis on INKT ...

Cancer does not develop overnight. It can take decades for cancer‐promoting changes in the genome to eventually lead to the ...

MiNK Therapeutics shares soared after the company published a case in a scientific journal of a cancer patient achieving remission after being treated with the company's cell therapy. Shares of the ...

MiNK Therapeutics surged on tumor remission data for agenT-797, but financial risks and limited clinical proof remain. Learn ...

MiNK Therapeutics stock surged 213% in premarket trading following the publication of a landmark case study showing complete ...

MiNK Therapeutics (NASDAQ:INKT) stock fell 30% on Monday, paring a massive 730% gain from Friday after William Blair downgraded the shares following the spectacular rally.

DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

The scientific journal Nature wants to show people the nitty gritty of academic publishing. In a Monday editorial, the journal announced it would include peer review files with the papers it ...

Most genes are ancient and shared across species. But a small subset of genes are relative newcomers, spontaneously emerging ...

In a bid to better understand how cancer cells power their explosive growth and spread, scientists at Johns Hopkins Medicine ...